Oily Phenol Injection 5% w/v

Summary of Product Characteristics Updated 13-Aug-2018 | Martindale Pharma, an Ethypharm Group Company

1. Name of the medicinal product

Oily Phenol 5% w/v Injection.

2. Qualitative and quantitative composition

Each ml of solution contains 50 mg Phenol.

3. Pharmaceutical form


4. Clinical particulars
4.1 Therapeutic indications

Analgesic sclerosing agent in the treatment of internal haemorrhoids

4.2 Posology and method of administration


Adults and the elderly

2- 3 ml of oily phenol injection into the sub-mucosal layer at the base of the haemorrhoid. Several sites may be injected but the maximum total at any one time is 10 ml.

Paediatric population

The use of oily phenol injection is contraindicated in children and neonates (see section 4.3).


No alternative dosage schedules have been suggested.

Method of administration

By submucosal injection

4.3 Contraindications

Oily Phenol Injection, is contraindicated in patients who are hypersensitive to phenol, nuts and in particular almond oil or any component of the product.

It should not be used over large areas, since sufficient amounts may be absorbed to give rise to toxic symptoms.

Oily Phenol Injection, is also contraindicated in neonates and children.

4.4 Special warnings and precautions for use

For submucosal injection only. Not for intrathecal use. Care should also be taken to avoid accidental intravenous injection. The injection may cause severe pain if it is too close to the anal verge. Complications of therapy can include local ulceration and sterile abscess formation. These complications may be serious following a misplaced injection (e.g. prostatic abscess). Care in choosing the correct site of injection is mandatory.

4.5 Interaction with other medicinal products and other forms of interaction

None stated

4.6 Fertility, pregnancy and lactation


Safety in pregnancy has not been established. The effects on the foetus are unknown, therefore Oily Phenol is not recommended for use during pregnancy.


It is not known whether Oily Phenol is excreted in breast milk. Since safety in infants has not been established, Oily Phenol injection is not recommended for use whilst breast-feeding.

4.7 Effects on ability to drive and use machines

Effects of phenol oily injection are not likely to affect the patient's ability to drive and use machinery.

4.8 Undesirable effects

General disorders and administration site conditions:






Tissue necrosis

Immune system disorders:


Nervous system disorders:


Hepatobiliary disorders:


Infections and infestations:


Prostatic abscess

Necrotizing fasciitis

Retroperitoneal sepsis

Renal and urinary disorders:


Urinary incontinence

Reproductive system and breast disorders:


Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

4.9 Overdose


The symptoms of overdosage after submucosal injection of Oily Phenol are not known, but are likely to be similar to symptoms observed after excessive exposure to phenol in other preparations. Absorption of phenol after application of dilute phenol solutions to extensive wounds has resulted in abdominal pains, dizziness, methaemoglobinaemia, haemoglobinurea, cyanosis, cardiac arrhythmias, ECG abnormalities, and may result in respiratory failure, circulatory failure, coma and death.


There is no specific antidote for actute phenol overdose. Treatment of overdose is symptomatic and supportive. If the product has been swallowed, empty the stomach by aspiration and lavage, taking care to avoid perforation, before carrying out the above procedure.

5. Pharmacological properties
5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Antivaricose therapy

ATC Code: C05BB05

The injection produces submucosal fibrosis, fixing the mucosa to the underlying muscle.

5.2 Pharmacokinetic properties

Phenol is absorbed from the gastro-intestinal tract and through skin and mucous membranes. It is metabolised to phenylglucoronide and phenylsulphate and small amounts are oxidised to catechol and quinol which are mainly conjugated. The metabolites are excreted in the urine; on oxidation to quinones they may tint the urine green.

5.3 Preclinical safety data

No data available

6. Pharmaceutical particulars
6.1 List of excipients

Almond oil

6.2 Incompatibilities

Incompatible with alkaline salts, acetanilide, phenazone, piperazine, quinine salts, phenacetin and iron salts. Phenol coagulates albumin and gelatinises collodion.

6.3 Shelf life

3 years (36 month) when packaged in glass ampoules

18 months when packaged in glass vials with rubber caps and aluminum crimps.

6.4 Special precautions for storage

Not applicable

6.5 Nature and contents of container

Clear glass ampoules containing 2 ml or 5 ml of product. 10 ampoules are packed into cartons. Glass vials containing 25 ml of product closed with rubber bungs sealed with aluminum caps. Not all pack sizes may be marketed.

6.6 Special precautions for disposal and other handling


7. Marketing authorisation holder

Macarthys Laboratories Limited

T/A Martindale Pharmaceuticals

Martindale Pharmaceuticals

Bampton Road, Romford, RM3 8UG.

8. Marketing authorisation number(s)

PL 01883/6153R

9. Date of first authorisation/renewal of the authorisation

First authorised: 22nd June, 1989

Last renewal:18th October, 1994

10. Date of revision of the text


Company Contact Details
Martindale Pharma, an Ethypharm Group Company

Jupiter House, Mercury Park, Wooburn Green, High Wycombe, Buckinghamshire, HP10 0HH, UK


+44 (0) 1277 266 600



Medical Information e-mail